ER

Erasca

NASDAQ: ERAS

San Diego, US · Founded 2018 · Delaware corporation · 7 known investors

erasca.com ↗

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

Investors · 7

AN

Andreessen HorowitzMenlo Park · $500K – $50M

AR

ARCH Venture PartnersChicago · $50K – $250Mvia Kristina Burow · quoted

EV

Evolution VC PartnersNew York

FR

Frazier Life SciencesPalo Alto

CI

City Hill VenturesreportedSan Diego · $100K – $20M

CO

Colt VenturesreportedDallas · $15M

LI

LifeSci Venture PartnersreportedNew York

Reported raises · per SEC filings

Form D private placements

▶$125.4MraisedApr 2020 · 46 investors · Biotechnology

Rule 506(b)

Erasca Raises $200M Series B Financingerasca.com · Apr 2020

Officers, directors & promoters on the filing

• Pratik S. Multani, M.D.Director
• Jonathan E. Lim, M.D.Director
• Valerie Harding-StartDirector
• Alexander W. CasdinDirector
• James A. Bristol, Ph.D.Director
• Jonathan E. Lim, M.D.Executive Officer, Director

Offering amount

$374.5M

Amount sold

$125.4M

First sale

Apr 2020

Incorporated

Corporation, Delaware, 2018

Federal exemptions

06b

Full filing on SEC EDGAR ↗

▶$58.3MraisedMar 2019 · 41 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

• Pratik S. Multani, M.D.Director
• Valerie Harding-StartDirector
• Jonathan E. Lim, M.D.Executive Officer, Director
• Gary Yeung, CFAExecutive Officer
• Alexander W. CasdinDirector
• James A. Bristol, Ph.D.Director

Offering amount

$70M

Amount sold

$58.3M

First sale

Oct 2018

Incorporated

Corporation, Delaware, 2018

Federal exemptions

06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.